Completed PHASE1 INTERVENTIONAL 4-arm NCT01919944

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

A Randomized, Double-Blind, Placebo-Controlled, Four-Way Crossover Study on Itch Control by VLY-686 Administration in Healthy Volunteers After Intradermal Injections of Substance P

Sponsor: Vanda Pharmaceuticals

Conditions Pruritus

Interventions Placebo VLY-686

Updated 6 times since 2017 Last updated: Jun 1, 2015 Started: Aug 31, 2013 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pruritus, this trial is completed. The trial is conducted by Vanda Pharmaceuticals and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vanda Pharmaceuticals

Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Arzo, Switzerland